United Therapeutics (UTHR) Set to Announce Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect United Therapeutics to post earnings of $6.16 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the company earned $5.24 earnings per share. United Therapeutics’s revenue was up 19.8% on a year-over-year basis. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.

United Therapeutics Stock Performance

Shares of UTHR opened at $348.65 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The stock has a 50-day moving average of $354.00 and a two-hundred day moving average of $313.31. The stock has a market cap of $15.46 billion, a P/E ratio of 16.48, a P/E/G ratio of 1.27 and a beta of 0.57. United Therapeutics has a one year low of $208.62 and a one year high of $377.03.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 102,812 shares of company stock valued at $35,251,926. 12.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on UTHR shares. Jefferies Financial Group upped their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. UBS Group increased their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Oppenheimer boosted their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $310.00 to $321.00 in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.